Bocouture 50 Units

Opis

Bocouture 50 Units (incobotulinumtoxinA) is a purified, complexing-protein-free botulinum neurotoxin type A manufactured by Merz Pharmaceuticals. Unlike some botulinum toxins that contain accessory proteins, Bocouture’s unique formulation eliminates these proteins, resulting in a lower potential for neutralizing antibody formation and more consistent long-term efficacy with repeated treatments. It works by inhibiting acetylcholine release at the neuromuscular junction, causing temporary, targeted muscle relaxation to reduce hyperkinetic facial lines or pathological muscle overactivity.

In aesthetic medicine, Bocouture 50 Units is approved (as Xeomin in some markets) for the temporary improvement of moderate to severe glabellar frown lines, lateral canthal lines (crow’s feet), and horizontal forehead lines in adults. The 50-unit vial is particularly suitable for:

• Smaller treatment areas (e.g., periorbital lines, bunny lines, lip lines)
• Subtle or preventative treatments
• Patients new to neuromodulators or those who prefer conservative dosing
• Men or individuals with stronger facial muscles requiring precise adjustments

Typical cosmetic doses range from 10–30 units per session for smaller areas or subtle corrections, with results becoming visible within 3–7 days, peaking at 2–4 weeks, and lasting 3–5 months depending on muscle strength, metabolism, and injection technique.

Therapeutically, Bocouture is indicated for:

• Blepharospasm (involuntary eyelid closure)
• Cervical dystonia (spasmodic torticollis)
• Chronic sialorrhea (excessive drooling) in adults and children ≥2 years
• Upper limb spasticity in adults and children ≥2 years

Dosing varies widely by indication (e.g., 10–100 units total for dystonia/spasticity), requiring precise anatomical placement by trained injectors. Bocouture 50 Units is supplied as lyophilized powder in a 50-unit vial, reconstituted with preservative-free 0.9% sodium chloride solution (typically 0.5–1.25 mL depending on desired concentration). The reconstituted solution remains stable for 24 hours refrigerated.

Common side effects include temporary injection-site reactions (pain, swelling, redness, bruising), headache, eyelid ptosis (drooping), dry eyes, or mild flu-like symptoms. Rare but serious risks include distant spread of toxin effects (swallowing/breathing difficulties), allergic reactions, or antibody-induced treatment failure (lower risk with Bocouture’s protein-free profile). Contraindications include known hypersensitivity to botulinum toxin or excipients, active infection at the injection site, and certain neuromuscular disorders (e.g., myasthenia gravis).

Bocouture 50 Units must be administered only by qualified healthcare professionals (dermatologists, plastic surgeons, neurologists, ophthalmologists, or aesthetic physicians) trained in botulinum toxin injection techniques. As of 2026, it is approved in many countries (including the US as Xeomin, Europe as Bocouture, and others) for both aesthetic and therapeutic indications, with ongoing research expanding its applications in pain management, overactive bladder, and other hypersecretory or hypertonic conditions. Always use under medical supervision with proper patient assessment, informed consent, and post-treatment follow-up. Bocouture 50 Units provides reliable, precise, natural-looking results with a clean, low-immunogenicity profile when used appropriately.